Romain Capoulade1, Xin Zeng1, Jessica R Overbey1, Gorav Ailawadi1, John H Alexander1, Deborah Ascheim1, Michael Bowdish1, Annetine C Gelijns1, Paul Grayburn1, Irving L Kron1, Robert A Levine1, Michael J Mack1, Serguei Melnitchouk1, Robert E Michler1, John C Mullen1, Patrick O'Gara1, Michael K Parides1, Peter Smith1, Pierre Voisine1, Judy Hung2. 1. From Division of Cardiology (R.C., X.Z., R.A.L., J.H.) and Department of Surgery (S.M.), Massachusetts General Hospital, Boston, MA; Department of Population Health Science and Policy/Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.R.O., D.A., A.C.G., M.K.P.); Department of Surgery Heart and Vascular Center, University of Virginia Health System, Charlottesville, VA (G.A., I.L.K.); Division of Cardiology, Duke Clinical Research Institute (J.H.A.) and Department of Surgery (P.S.), Duke Medicine, Durham, NC; Department of Surgery, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA (M.B.); Department of Cardiology, Baylor Heart and Vascular Institute, Dallas, TX (P.G.); Department of Cardiovascular Medicine, Baylor Scott & White Health, Plano, TX (M.J.M.); Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY (R.E.M.); Department of Surgery, Mackenzie Health Sciences Center, Edmonton, AB, Canada (J.C.M.); Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (P.O.); and Department of Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, QC, Canada (P.V.). 2. From Division of Cardiology (R.C., X.Z., R.A.L., J.H.) and Department of Surgery (S.M.), Massachusetts General Hospital, Boston, MA; Department of Population Health Science and Policy/Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.R.O., D.A., A.C.G., M.K.P.); Department of Surgery Heart and Vascular Center, University of Virginia Health System, Charlottesville, VA (G.A., I.L.K.); Division of Cardiology, Duke Clinical Research Institute (J.H.A.) and Department of Surgery (P.S.), Duke Medicine, Durham, NC; Department of Surgery, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA (M.B.); Department of Cardiology, Baylor Heart and Vascular Institute, Dallas, TX (P.G.); Department of Cardiovascular Medicine, Baylor Scott & White Health, Plano, TX (M.J.M.); Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY (R.E.M.); Department of Surgery, Mackenzie Health Sciences Center, Edmonton, AB, Canada (J.C.M.); Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (P.O.); and Department of Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, QC, Canada (P.V.). jhung@mgh.harvard.edu.
Abstract
BACKGROUND: In ischemic mitral regurgitation (IMR), ring annuloplasty is associated with a significant rate of recurrent MR. Ring size is based on intertrigonal distance without consideration of left ventricular (LV) size. However, LV size is an important determinant of mitral valve (MV) leaflet tethering before and after repair. We aimed to determine whether LV-MV ring mismatch (mismatch of LV size relative to ring size) is associated with recurrent MR in patients with IMR after restrictive ring annuloplasty. METHODS:Patients with moderate or severe IMR from the 2 Cardiothoracic Surgical Trials Network IMR trials who receivedMV repair were examined at 1 year after surgery. Baseline LV size was assessed by LV end-diastolic dimension and LV end-systolic dimension (LVESd). LV-MV ring mismatch was calculated as the ratio of LV to ring size (LV end-diastolic dimension/ring size and LVESd/ring size). RESULTS: At 1 year after ring annuloplasty, 45 of 214 patients with MV repair (21%) had moderate or greater MR. In univariable logistic regression analysis, larger LVESd (P=0.02) and LVESd/ring size (P=0.007) were associated with recurrent MR. In multivariable models adjusted for age, sex, baseline LV ejection fraction, and severe IMR, only LVESd/ring size (odd ratio per 0.5 increase, 2.20; 95% confidence interval, 1.05-4.62; P=0.038) remained significantly associated with 1-year MR recurrence. CONCLUSIONS: LV-MV ring size mismatch is associated with increased risk of MR recurrence. This finding may be helpful in guiding choice of ring size to prevent recurrent MR in patients undergoing MV repair and in identifying patients who may benefit from MV repair with additional subvalvular intervention or MV replacement rather than repair alone. CLINICAL TRIAL REGISTRATION: URL:http://clinicaltrials.gov. Unique identifiers: NCT00806988 and NCT00807040.
RCT Entities:
BACKGROUND: In ischemic mitral regurgitation (IMR), ring annuloplasty is associated with a significant rate of recurrent MR. Ring size is based on intertrigonal distance without consideration of left ventricular (LV) size. However, LV size is an important determinant of mitral valve (MV) leaflet tethering before and after repair. We aimed to determine whether LV-MV ring mismatch (mismatch of LV size relative to ring size) is associated with recurrent MR in patients with IMR after restrictive ring annuloplasty. METHODS:Patients with moderate or severe IMR from the 2 Cardiothoracic Surgical Trials Network IMR trials who received MV repair were examined at 1 year after surgery. Baseline LV size was assessed by LV end-diastolic dimension and LV end-systolic dimension (LVESd). LV-MV ring mismatch was calculated as the ratio of LV to ring size (LV end-diastolic dimension/ring size and LVESd/ring size). RESULTS: At 1 year after ring annuloplasty, 45 of 214 patients with MV repair (21%) had moderate or greater MR. In univariable logistic regression analysis, larger LVESd (P=0.02) and LVESd/ring size (P=0.007) were associated with recurrent MR. In multivariable models adjusted for age, sex, baseline LV ejection fraction, and severe IMR, only LVESd/ring size (odd ratio per 0.5 increase, 2.20; 95% confidence interval, 1.05-4.62; P=0.038) remained significantly associated with 1-year MR recurrence. CONCLUSIONS: LV-MV ring size mismatch is associated with increased risk of MR recurrence. This finding may be helpful in guiding choice of ring size to prevent recurrent MR in patients undergoing MV repair and in identifying patients who may benefit from MV repair with additional subvalvular intervention or MV replacement rather than repair alone. CLINICAL TRIAL REGISTRATION: URL:http://clinicaltrials.gov. Unique identifiers: NCT00806988 and NCT00807040.
Authors: Paul A Grayburn; Blasé Carabello; Judy Hung; Linda D Gillam; David Liang; Michael J Mack; Patrick M McCarthy; D Craig Miller; Alfredo Trento; Robert J Siegel Journal: J Am Coll Cardiol Date: 2014-12-30 Impact factor: 24.094
Authors: A M Calafiore; S Gallina; M Di Mauro; F Gaeta; A L Iacò; S D'Alessandro; V Mazzei; G Di Giammarco Journal: Ann Thorac Surg Date: 2001-04 Impact factor: 4.330
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas Journal: Circulation Date: 2014-03-03 Impact factor: 29.690
Authors: Allen Cheng; Tom C Nguyen; Marcin Malinowski; David Liang; George T Daughters; Neil B Ingels; D Craig Miller Journal: Circulation Date: 2006-07-04 Impact factor: 29.690
Authors: Irving L Kron; Judy Hung; Jessica R Overbey; Denis Bouchard; Annetine C Gelijns; Alan J Moskowitz; Pierre Voisine; Patrick T O'Gara; Michael Argenziano; Robert E Michler; Marc Gillinov; John D Puskas; James S Gammie; Michael J Mack; Peter K Smith; Chittoor Sai-Sudhakar; Timothy J Gardner; Gorav Ailawadi; Xin Zeng; Karen O'Sullivan; Michael K Parides; Roger Swayze; Vinod Thourani; Eric A Rose; Louis P Perrault; Michael A Acker Journal: J Thorac Cardiovasc Surg Date: 2014-11-06 Impact factor: 5.209
Authors: Edwin C McGee; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Gideon Cohen; Farzad Najam; Takahiro Shiota; Joseph F Sabik; Bruce W Lytle; Patrick M McCarthy; Delos M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 2004-12 Impact factor: 5.209
Authors: Judy Hung; Lampros Papakostas; Stephen A Tahta; Bruce G Hardy; Bruce A Bollen; Carlos M Duran; Robert A Levine Journal: Circulation Date: 2004-09-14 Impact factor: 29.690
Authors: Michael A Acker; Michael K Parides; Louis P Perrault; Alan J Moskowitz; Annetine C Gelijns; Pierre Voisine; Peter K Smith; Judy W Hung; Eugene H Blackstone; John D Puskas; Michael Argenziano; James S Gammie; Michael Mack; Deborah D Ascheim; Emilia Bagiella; Ellen G Moquete; T Bruce Ferguson; Keith A Horvath; Nancy L Geller; Marissa A Miller; Y Joseph Woo; David A D'Alessandro; Gorav Ailawadi; Francois Dagenais; Timothy J Gardner; Patrick T O'Gara; Robert E Michler; Irving L Kron Journal: N Engl J Med Date: 2013-11-18 Impact factor: 91.245
Authors: Francesco Nappi; Sanjeet Singh Avtaar Singh; Muralidhar Padala; David Attias; Mohammed Nejjari; Christos G Mihos; Umberto Benedetto; Robert Michler Journal: Ann Thorac Surg Date: 2019-08-22 Impact factor: 4.330
Authors: Jiwon Kim; Javid Alakbarli; Maria Chiara Palumbo; Lola X Xie; Lisa Q Rong; Nathan H Tehrani; Lillian R Brouwer; Richard B Devereux; Shing Chiu Wong; Geoffrey W Bergman; Omar K Khalique; Robert A Levine; Mark B Ratcliffe; Jonathan W Weinsaft Journal: Catheter Cardiovasc Interv Date: 2019-02-21 Impact factor: 2.692
Authors: Christos G Mihos; Steve Xydas; Evin Yucel; Romain Capoulade; Roy F Williams; Maurice Mawad; Guillermo Garcia; Orlando Santana Journal: J Thorac Dis Date: 2017-06 Impact factor: 2.895
Authors: Bart S. Ferket; Gorav Ailawadi; Annetine C. Gelijns; Michael Acker; Samuel F. Hohmann; Helena L. Chang; Denis Bouchard,; David O. Meltzer; Robert E. Michler; Ellen G. Moquete; Pierre Voisine; John C. Mullen; Anuradha Lala; Michael J. Mack; A. Marc Gillinov; Vinod H. Thourani; Marissa A. Miller; James S. Gammie; Michael K. Parides; Emilia Bagiella; Robert L. Smith; Peter K. Smith; Judy W. Hung; Lopa N. Gupta; Eric A. Rose; Patrick T. O'Gara; Alan J. Moskowitz Journal: Circ Cardiovasc Qual Outcomes Date: 2018-11-14